+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Targeting the mTOR signaling network for cancer therapy.

      Journal of clinical oncology : official journal of the American Society of Clinical Oncology
      Biological Markers, Clinical Trials as Topic, Humans, Neoplasms, drug therapy, Patient Selection, Protein Kinases, drug effects, physiology, Signal Transduction, Sirolimus, analogs & derivatives, therapeutic use, TOR Serine-Threonine Kinases

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The serine-threonine kinase mammalian target of rapamycin (mTOR) plays a major role in the regulation of protein translation, cell growth, and metabolism. Alterations of the mTOR signaling pathway are common in cancer, and thus mTOR is being actively pursued as a therapeutic target. Rapamycin and its analogs (rapalogs) have proven effective as anticancer agents in a broad range of preclinical models. Clinical trials using rapalogs have demonstrated important clinical benefits in several cancer types; however, objective response rates achieved with single-agent therapy have been modest. Rapalogs may be more effective in combination with other anticancer agents, including chemotherapy and targeted therapies. It is increasingly apparent that the mTOR signaling network is quite complex, and rapamycin treatment leads to different signaling responses in different cell types. A better understanding of mTOR signaling, the mechanism of action of rapamycin, and the identification of biomarkers of response will lead to more optimal targeting of this pathway for cancer therapy.

          Related collections

          Author and article information


          Comment on this article